参考文献

［1］中华人民共和国卫生部.2000年全国结核病流行病学抽样调查资料汇编［M］.北京：人民卫生出版社，2003.

［2］DYE C，SCHEELE S，DOLIN P，et al.Consensus statement.Global burden of tuberculosis:Estimated incidence，prevalence，and mortality by country.WHO Global Surveillance and Monitoring Project［J］.Journal of the American Medical Association，1999，282（7）:677-686.

［3］DYE C，BASSILI A，BIERRENBACH A L，et al.Measuring tuberculosis burden，trends and the impact of control programmes［J］.Lancet Infectious Diseases，2008，8（4）:233-243.

［4］WERF M J，BORGDORFF M W.Targets for tuberculosis control:how confident can we be about the data［J］.Bulletin of the World Health Organization，2007，85（5）:370-376.

［5］WORLD HEALTH ORGANIZATION.Global Tuberculosis Report 2020［R/OL］.2020.https://www.who.int/publications/i/item/global-tuberculosis-report-2020.

［6］WHO.TB Impact Measurement:Policy and recommendations for how to assess the epidemiological burden of TB and the impact of TB control［R/OL］.2009.http://whqlibdoc.who.int/publications/2011/9789241548168_eng.pdf.

［7］CHINA TUBERCULOSIS CONTROL COLLABORATION.The effect of tuberculosis control in China［J］.Lancet，2004，364（9432）:417-422.

［8］YANG G H，RAO C，MA J M，et al.Validation of verbal autopsy procedures for adult deaths in China［J］.International Journal of Epidemiology，2006，35（3）:741-748.

［9］SUTHAR A B，LAWN S D，AMO J D，et al.Antiretroviral therapy for prevention of tuberculosis in adults with HIV:a systematic review and meta-analysis［J］.PLoS Med，2012，9（7）:e1001270.

［10］WORLD HEALTH ORGANIZATION.Global Tuberculosis Report 2015［R/OL］.2015.https://apps.who.int/iris/bitstream/handle/10665/191102/9789241565059_eng.pdf.

［11］DYE C.Global epidemiology of tuberculosis［J］.Lancet，2006，367（9514）:938-940.

［12］HAVLIR D V，GETAHUN H，SANNE I，et al.Opportunities and challenges for HIV care inoverlapping HIV and TB epidemics［J］.JAMA，2008，300（4）:423-430.

［13］ONOZAKI I，LAW I，SISMANIDIS C，et al.National tuberculosis prevalence surveys in Asia，1990—2012:an overview of results and lessons learned［J］.Trop Med Int Health，2015，20（9）:1128-1145.

［14］WARNER D F，KOCH A，MIZRAHI V.Diversity and disease pathogenesis in Mycobacterium tuberculosis［J］.Trends Microbiol，2015，23（1）:14-21.

［15］SIMEONE R，BOBARD A，LIPPMANN J，et al.Phagosomal rupture by Mycobacterium tuberculosis results intoxicity and host cell death［J］.PLoS Pathog，2012，8（2）:e1002507.

［16］AREND S M，MEIJGAARDEN K E，BOER K，et al.Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M.Kansasii［J］.J Infect Dis，2002，186（12）:1797-1807.

［17］PAI M，DENKINGER C M，KIK S V，et al.Gamma interferon release assays for detection of Mycobacterium tuberculosis infection［J］.Clin Microbiol Rev，2014，27（1）:3-20.

［18］PANDE T，PAI M，KHAN F A，et al.Use of chest radiography in the 22 highest tuberculosis burden countries［J］.Eur Respir J，2015，46（6）:1816-1819.

［19］ALBERT H，NATHAVITHARANA R R，ISAACS C，et al.Development，roll-out，and impact of Xpert MTB/RIF for tuberculosis:what lessons have we learnt，and how can we do better？［J］.Eur Respir J，2016，48（2）:516-525.

［20］UNITAID.Tuberculosis:Diagnostics Technology and Market Landscape［M/OL］.4th edition.2015.http://unitaid.org/assets/Tuberculosis_diagnostics_technology_and_market_landscape_4th_edition_Oct_2015-1.pdf.

［21］NAHID P，DORMAN S E，ALIPANAH N，et al.Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines:treatment of drug-susceptible tuberculosis［J］.Clin Infect Dis，2016，63（7）:e147-e195.

［22］SAMANDARI T，AGIZEW T B，NYIRENDA S，et al.6-Month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana:a randomised，double-blind，placebocontrolled trial［J］.Lancet，2011，377（9777）:1588-1598.

［23］DHEDA K，SHEAN K，ZUMLA A，et al.Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa:a retrospective cohort study［J］.Lancet，2010，375（9728）:1798-1807.

［24］TAMERIS M D，HATHERILL M，LANDRY B S，et al.Safety and efficacy of MVA85A，a new tuberculosis vaccine，in infants previously vaccinated with BCG:a randomised，placebo-controlled phase 2b trial［J］.Lancet，2013，381（9871）:1021-1028.

［25］MANGTANI P，ABUBAKAR I，ARITI C，et al.Protection by BCG vaccine against tuberculosis:a systematic review of randomized controlled trials［J］.Clin Infect Dis，2014，58（4）:470-480.

［26］ELLIS R D，HATHERILL M，TAIT D，et al.Innovative clinical trial designs to rationalize TB vaccine development［J］.Tuberculosis（Edinb），2015，95（3）:352-357.

［27］AERAS.TB vaccine research and development:a business case for investment［EB/OL］.2014.http://www.aeras.org/pdf/TB_RD_Business_Case_Draft_3.pdf.

［28］TUBERCULOSIS RESEARCH CENTRE（ICMR）.Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention［J］.Indian J Med Res，2013，137（3）:571-585.

［29］WELLS W A，UPLEKAR M，PAI M.Achieving systemic and scalable private sector engagement in tuberculosis care and prevention in Asia［J］.PLoS Med，2015，12（6）:e1001842.

［30］中华人民共和国卫生部.1979年全国结核病流行病学抽样调查资料汇编［M］.北京：人民卫生出版社，1981.

［31］中华人民共和国卫生部.1984/1985年全国结核病学流行病学抽样调查资料汇编［M］.北京：人民卫生出版社，1988.

［32］中华人民共和国卫生部.1990年全国结核病学流行病学抽样调查资料汇编［M］.北京：人民卫生出版社，1992.

［33］王陇德.结核病防治［M］.北京:中国协和医科大学出版社，2004. MtT/AC0Ahenaqp9LXw0h4/i0OhjVwvGS8GfevmxFnMOn0A35XUc07Dw15oiorVz7